hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53.
To identify p53-target genes we have been using a cDNA-microarray system to assess gene expression in a p53-mutated glioblastoma cell line (U373MG) after adenovirus-mediated transfer of wild-type p53 into the p53-deficient cells. In the work reported here, expression of hCDC4b, which encodes one of the four subunits of the SCF (ubiquitin ligase) complex responsible for degradation of cyclin E, was dramatically up-regulated by infection with Ad-p53. An electrophoretic mobility-shift assay and a chromatin immunoprecipitation assay indicated that a potential p53-binding site (p53BS) present in exon 1b of the hCDC4 gene was able to bind to p53, and a reporter assay confirmed that this p53BS had p53-dependent transcriptional activity. Expression of endogenous hCDC4b, but not the alternative transcript of this gene, hCDC4a, was induced in a p53-dependent manner in response to genotoxic stresses caused by UV irradiation and adriamycin treatment, suggesting that each transcript has a different functional role. These results suggest that hCDC4b is a previously unrecognized transcriptional target of the p53 protein, and that by negatively regulating cyclin E through induction of hCDC4b, p53 might stop cell-cycle progression at G0-G1. This would represent a novel mechanism for p53-dependent control of the cell cycle, in addition to the well-known p21(WAF1) machinery.
Kimura
Takashi
T
Human Genome Center, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Gotoh
Mitsukazu
M
Nakamura
Yusuke
Y
Arakawa
Hirofumi
H
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001483:Base Sequence; D019556:COS Cells; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism*; D002522:Chlorocebus aethiops; D002843:Chromatin / Q000378:metabolism; D019927:Cyclin E / Q000235:genetics / Q000378:metabolism*; D018076:DNA, Complementary / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology; D024202:Electrophoretic Mobility Shift Assay; D044783:F-Box Proteins / Q000235:genetics / Q000378:metabolism*; D000073979:F-Box-WD Repeat-Containing Protein 7; D020869:Gene Expression Profiling; D016158:Genes, p53 / Q000502:physiology*; D006801:Humans; D007527:Isoenzymes; D008969:Molecular Sequence Data; D020411:Oligonucleotide Array Sequence Analysis; D021381:Protein Transport; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000378:metabolism*; D014466:Ultraviolet Rays
D000903:Antibiotics, Antineoplastic; D018797:Cell Cycle Proteins; D002843:Chromatin; D019927:Cyclin E; D018076:DNA, Complementary; D044783:F-Box Proteins; D000073979:F-Box-WD Repeat-Containing Protein 7; C513273:FBXW7 protein, human; D007527:Isoenzymes; D004317:Doxorubicin; D044767:Ubiquitin-Protein Ligases